drugset / Trial / NCT02561650

Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions

NCT02561650

Phase 1 Completed 48 enrolled Mallinckrodt
NaSingle-groupOpen-label

Summary

A single center, single dose, open-label, randomized, 3-period, 6-sequence, crossover study conducted in normal healthy subjects to evaluate the effect of a high- and low-fat meal on the pharmacokinetics (PK), bioavailability (BA), and safety of COV155.

Timeline

Start
2011-12
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject COV155 Unknown

Indications

No indication recorded.